Privately held Thrasos Therapeutics has raised $35 million in financing from a consortium of investors to take THR-184 — its lead compound for the treatment of acute kidney injury — through to Phase II clinical proof of concept. Investors in the Montreal-based firm are: SR One, GSK Life Sciences Innovation Fund, SW Co, Advanced Technology Ventures, Fonds de solidarité FTQ, Lumira Capital, MP Healthcare Venture Management and Pappas Ventures....